Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $11.7 million.

  • Amicus Therapeutics' Interest Expenses fell 772.93% to $11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.7 million, marking a year-over-year decrease of 748.61%. This contributed to the annual value of $49.6 million for FY2024, which is 109.87% down from last year.
  • Amicus Therapeutics' Interest Expenses amounted to $11.7 million in Q3 2025, which was down 772.93% from $11.6 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Interest Expenses peaked at $13.0 million during Q3 2023, and registered a low of $8.0 million during Q1 2021.
  • Moreover, its 5-year median value for Interest Expenses was $11.6 million (2025), whereas its average is $10.7 million.
  • In the last 5 years, Amicus Therapeutics' Interest Expenses soared by 12420.91% in 2021 and then crashed by 788.84% in 2025.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Interest Expenses stood at $8.2 million in 2021, then soared by 35.9% to $11.1 million in 2022, then increased by 15.61% to $12.8 million in 2023, then fell by 6.77% to $12.0 million in 2024, then dropped by 2.07% to $11.7 million in 2025.
  • Its Interest Expenses was $11.7 million in Q3 2025, compared to $11.6 million in Q2 2025 and $11.5 million in Q1 2025.